Feature | March 27, 2012

Antiplatelet Drug Reduces Damage to Heart Muscle in Heart Attack Patients

Results of the INFUSE-AMI trial presented at ACC; clot aspiration not effective

Atrium Medicals ClearPath infusion catheter.

Medtronics Export aspiration catheter.

Data from the INFUSE-AMI trial, showing little difference in patients treated with clot aspiration, versus no aspiration.

Data from the INFUSE-AMI trial, showing little difference in patients treated with clot aspiration, versus no aspiration.

March 27, 2012 – Researchers found the antiplatelet drug abciximab significantly decreased damage to the heart muscle in patients with ST-segment-elevation myocardial infarction (STEMI), the most severe type of heart attack. Results of the INFUSE-AMI trial were presented at the American College of Cardiology’s 61st Annual Scientific Session and published simultaneously in the March 25 online issue of the Journal of the American Medical Association. Researchers also found that clot aspiration did not significantly reduce the damage to the heart muscle.

“Results from the INFUSE-AMI trial suggest that in patients with large heart attacks reaching the hospital early, the extent of heart damage can be reduced with a bolus of intracoronary abciximab delivered directly to the infarct lesion,” said lead investigator, Gregg W. Stone, M.D. He is professor of medicine at Columbia University College of Physicians and Surgeons, and director of research and education at the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital. Stone also serves as co-director of the medical research and education division at the Cardiovascular Research Foundation.

The primary efficacy endpoint was heart attack size at 30 days, as measured by cardiac magnetic resonance imaging (MRI) for 382 of 439 surviving patients (87.1%). Abciximab was delivered locally to the site of the blocked artery using a novel catheter, the ClearWay Rx (Atrium Medical). Heart attack size was measured by calculating infarct size as a percentage of total heart muscle tissue. Patients in the two abciximab arms had significantly smaller heart attacks than patients in the two no-abciximab arms (median 15.1 vs. 17.9%).

In contrast, aspiration thrombectomy did not significantly decrease heart attack size (17%) compared with no aspiration (17.3%). The aspiration plus abciximab group showed the lowest median heart attack size of 14.7%, compared with 17.6% for the other three groups combined. There were no significant differences among the four groups for any major measures of safety or efficacy at 30 days. Patients will be assessed again at six months and one year.

“A large randomized clinical trial of intracoronary abciximab delivered to the site of the infarct lesion through the ClearWay Rx catheter is needed to determine whether this therapy results in improved clinical outcomes without excessive bleeding,” Stone said.

“Additionally, in this trial, aspiration did not reduce infarct size. However, the final word about aspiration in STEMI will be spoken by the results from two large ongoing randomized trials of aspiration powered for mortality,” Stone added. These trials include TOTAL and TASTE.

The INFUSE-AMI trial used a 2 x 2 factorial design, isolating the impact of each intervention to maximize the chance of identifying any reduction in heart attack size. The trial, conducted at 37 sites in six countries, screened 6,318 patients and enrolled only 452 (7.2 percent) with large heart attacks presenting early, during the time when reduction in the size of the heart attack is still possible. The trial was a single-blind study in which the operator knew the randomization assignments.

All study subjects were treated with the anticoagulant bivalirudin, and randomly assigned to one of four arms: (1) aspiration plus abciximab, (2) aspiration without abciximab, (3) no aspiration plus abciximab, and (4) no aspiration or abciximab (control). In the two abciximab arms, a balloon catheter (ClearWay Rx) delivered the drug right to the site of the lesion, which invariably has thrombus present. Aspiration was accomplished through an Export (Medtronic) catheter. All patients who had angioplasty were also treated with bivalirudin, an anticoagulant that keeps bleeding and mortality low.

The INFUSE-AMI trial was funded by Atrium Medical, manufacturer of the ClearWay RX catheter, and Medtronic Inc., manufacturer of the Export catheter, and conducted by the Cardiovascular Research Foundation. Stone reported consulting fees from Abbott Vascular, Boston Scientific, Medtronic, Atrium, The Medicines Company, Merck, Daiichi Sankyo and Eli Lilly.

This study was simultaneously published in the Journal of the American Medical Association and released online at the time of presentation.

For more information: www.crf.org

Related Content

Hospital Readmissions Analysis Across All Ages, Insurance Types Identifies High-Risk Groups
News | Business| July 20, 2017
July 20, 2017 — Clinician-researchers at Beth Israel Deaconess Medical Center (BIDMC) recently published a first-of-i
3-D Vascular Ultrasound Quantifies Plaque Burden to Estimate Cardiovascular Risk
News | Cardiovascular Ultrasound| July 20, 2017
July 20, 2017 — In a large, first-of-its-kind population, researchers found an experimental technique known as...
More Than 20 Percent of Low-Risk Patients Receive Annual ECG
News | ECG| July 20, 2017
July 20, 2017 — More than one in five Ontario patients receive an ...
Sponsored Content | Videos | CT Angiography (CTA)| July 18, 2017
Matthew Budoff, M.D., FACC, professor of medicine, David Geffen School of Medicine at UCLA, endowed chair of preventi
Low Doses of Radiation Could Harm Cardiovascular Health
News | Radiation Dose Management| July 17, 2017
Ionizing radiation, such as X-rays, has a harmful effect on the cardiovascular system even at doses equivalent to...
First Patient Treated in U.S. Feasibility Study of LimFlow Critical Limb Ischemia Device
News | Peripheral Arterial Disease (PAD)| July 17, 2017
LimFlow SA announced enrollment of the first patient in the U.S. feasibility study of the LimFlow Percutaneous Deep...
Alere point of care POC testing for INR
News | Point of Care Testing| July 17, 2017 | Dave Fornell
July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is on
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Edwards Sapien 3 TAVR valve will be implanted in asymptomatic aortic stenosis patients in the EARLY TAVR Trial
Feature | Heart Valve Technology| July 14, 2017
July 14, 2017 — Morristown Medical Center, part of Atlantic Health System, has randomized the first patient in the wo
long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies| July 12, 2017
June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet ther
Overlay Init